Cargando…

Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction

BACKGROUND/AIMS: Acute coronary syndrome (ACS) is characterized by increased inflammatory processes and endothelial activation. We investigated the association between ACS and inflammatory mediators and matrix-degrading enzymes. METHODS: We prospectively enrolled 55 consecutive patients with ACS: 25...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzel, Savas, Serin, Ozden, Guzel, Eda Celik, Buyuk, Banu, Yılmaz, Güzin, Güvenen, Guvenc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604606/
https://www.ncbi.nlm.nih.gov/pubmed/23525523
http://dx.doi.org/10.3904/kjim.2013.28.2.165
_version_ 1782263768386895872
author Guzel, Savas
Serin, Ozden
Guzel, Eda Celik
Buyuk, Banu
Yılmaz, Güzin
Güvenen, Guvenc
author_facet Guzel, Savas
Serin, Ozden
Guzel, Eda Celik
Buyuk, Banu
Yılmaz, Güzin
Güvenen, Guvenc
author_sort Guzel, Savas
collection PubMed
description BACKGROUND/AIMS: Acute coronary syndrome (ACS) is characterized by increased inflammatory processes and endothelial activation. We investigated the association between ACS and inflammatory mediators and matrix-degrading enzymes. METHODS: We prospectively enrolled 55 consecutive patients with ACS: 25 with unstable angina (UA) and 30 with non-ST elevated myocardial infarction (NSTEMI). For comparison, 25 age- and sex-matched subjects with no significant coronary artery stenosis were included as the control group. Peripheral serum levels of interleukin (IL)-33, matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP-1, and C-reactive protein (CRP) were measured on admission, and at 12, 24, 48, and 72 hours after the initial evaluation. RESULTS: Compared to serum levels in the control group, serum levels of IL-33 decreased in the NSTEMI group (p < 0.05), and levels of MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 increased in the UA group (p < 0.01, p < 0.05, respectively) and NSTEMI group (p < 0.05, p < 0.05, respectively). IL-33 levels were significantly lower on admission than at 12 hours after the initial evaluation (p < 0.05). IL-33 levels were negatively correlated with MMP-9 levels (r = -0.461, p < 0.05) and CRP levels (r = -0.441, p < 0.05). CONCLUSIONS: Elevated levels of MMP-9, TIMP-1, and decreased levels of IL-33 play a role in the development and progression of ACS.
format Online
Article
Text
id pubmed-3604606
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-36046062013-03-22 Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction Guzel, Savas Serin, Ozden Guzel, Eda Celik Buyuk, Banu Yılmaz, Güzin Güvenen, Guvenc Korean J Intern Med Original Article BACKGROUND/AIMS: Acute coronary syndrome (ACS) is characterized by increased inflammatory processes and endothelial activation. We investigated the association between ACS and inflammatory mediators and matrix-degrading enzymes. METHODS: We prospectively enrolled 55 consecutive patients with ACS: 25 with unstable angina (UA) and 30 with non-ST elevated myocardial infarction (NSTEMI). For comparison, 25 age- and sex-matched subjects with no significant coronary artery stenosis were included as the control group. Peripheral serum levels of interleukin (IL)-33, matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP-1, and C-reactive protein (CRP) were measured on admission, and at 12, 24, 48, and 72 hours after the initial evaluation. RESULTS: Compared to serum levels in the control group, serum levels of IL-33 decreased in the NSTEMI group (p < 0.05), and levels of MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 increased in the UA group (p < 0.01, p < 0.05, respectively) and NSTEMI group (p < 0.05, p < 0.05, respectively). IL-33 levels were significantly lower on admission than at 12 hours after the initial evaluation (p < 0.05). IL-33 levels were negatively correlated with MMP-9 levels (r = -0.461, p < 0.05) and CRP levels (r = -0.441, p < 0.05). CONCLUSIONS: Elevated levels of MMP-9, TIMP-1, and decreased levels of IL-33 play a role in the development and progression of ACS. The Korean Association of Internal Medicine 2013-03 2013-02-27 /pmc/articles/PMC3604606/ /pubmed/23525523 http://dx.doi.org/10.3904/kjim.2013.28.2.165 Text en Copyright © 2013 The Korean Association of Internal Medicine http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Guzel, Savas
Serin, Ozden
Guzel, Eda Celik
Buyuk, Banu
Yılmaz, Güzin
Güvenen, Guvenc
Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
title Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
title_full Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
title_fullStr Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
title_full_unstemmed Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
title_short Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
title_sort interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604606/
https://www.ncbi.nlm.nih.gov/pubmed/23525523
http://dx.doi.org/10.3904/kjim.2013.28.2.165
work_keys_str_mv AT guzelsavas interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction
AT serinozden interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction
AT guzeledacelik interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction
AT buyukbanu interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction
AT yılmazguzin interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction
AT guvenenguvenc interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction